Oncology最新文献

{"title":"Real-World Outcomes in Acute Promyelocytic Leukemia: A 13-Year Cohort from Qatar.","authors":"Rola Ghasoub, Hesham Elsabah, Anas Hamad, Nabeel Mohammad Qasem, Hawraa Shwaylia, Feryal Ibrahim, Halima Elomri, Rajvir Singh, Shehab Fareed, Abdulrahman F Al-Mashdali, Anil Ellahie, Honar Cherif","doi":"10.1159/000553398","DOIUrl":"10.1159/000553398","url":null,"abstract":"<p><strong>Introduction: </strong>Acute promyelocytic leukemia (APL) is among the most curable acute leukemias, but real-world early mortality continues to undermine population-level cure. This study evaluated long-term outcomes and prognostic factors among adults with APL treated in a single tertiary center in Qatar.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of consecutive adult patients diagnosed with APL between 2012 and 2024. Baseline demographic, clinical, and laboratory data, treatment regimens, and response outcomes were extracted from electronic medical records. Patients were stratified according to Sanz risk criteria. Overall survival (OS) was estimated using the Kaplan-Meier method, and prognostic factors were assessed using log-rank tests and Cox proportional hazards regression.</p><p><strong>Results: </strong>A total of 87 patients were included (median age: 36 years; 47.1% high-risk groups by Sanz criteria). Early mortality within 30 days occurred in 26.4% (n = 23), predominantly due to intracranial hemorrhage (47.8% of early deaths). Among 71 patients who received treatment, the complete remission (CR) rate was 84.1%, with the highest CR observed in those treated with all-trans retinoic acid (ATRA)-arsenic trioxide (90.9%). Treatment-related complications occurred in 73.2% of patients, most commonly infections (66.2%) and differentiation syndrome (21.1%). Three-year OS was 93% in low-risk groups, 88% in intermediate-risk groups, and 56% in high-risk groups (log-rank p = 0.001). In multivariable analysis, ICU admission (hazard ratio [HR]: 5.42) and lack of treatment initiation (HR: 8.06) were independent predictors of mortality. Excluding patients presenting with intracranial hemorrhage, early mortality decreased to 14.7%, and 5-year OS improved to 87.6%.</p><p><strong>Conclusion: </strong>Despite the effectiveness of contemporary APL therapies, early mortality, primarily driven by hemorrhagic complications, remains a significant challenge. Strategies to improve outcomes should focus on rapid diagnosis, immediate initiation of empiric ATRA, and aggressive correction of coagulopathy. Integration of APL-specific emergency care pathways may represent a key opportunity to reduce preventable deaths.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-13"},"PeriodicalIF":1.9,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13461110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148382575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rising Lung Cancer Burden Attributable to High Fasting Plasma Glucose in Women Aged ≥50 Years: Age-, SDI-, and BRICS-Specific Patterns from GBD 1990-2021.","authors":"Lili Lin, Xiaoqin Huang, Bijun Li, Jinjian Li, Hui Chen","doi":"10.1159/000552661","DOIUrl":"10.1159/000552661","url":null,"abstract":"<p><strong>Introduction: </strong>We quantified trends and heterogeneity in lung cancer burden attributable to high fasting plasma glucose (HFPG) among women aged ≥50 years (used as a population-level proxy for postmenopausal status) globally and across BRICS countries from 1990 to 2021.</p><p><strong>Methods: </strong>HFPG-attributable lung cancer deaths and disability-adjusted life years (DALYs) for women aged ≥50 years were obtained from Global Burden of Disease 1990-2021. Burden was summarized as numbers and age-standardized rates (ASR) per 100,000, stratified by age, Socio-demographic Index (SDI) quintile, and country. Trends were assessed using estimated annual percentage change (EAPC) from log-linear regression.</p><p><strong>Results: </strong>Global HFPG-attributable deaths and DALYs increased markedly from 1990 to 2021, with rising ASR (global EAPC 1.21; 95% CI, 1.11-1.31). A strong age gradient was observed; EAPC increased from 0.53% (50-54 years) to 3.65% (≥95 years). In 2021, the DALYs ASR peaked in the 75-79 years group (59.38 per 100,000). High-SDI settings consistently had the highest ASR and increasing burden. In BRICS, the ASR of DALYs increased in all five countries with substantial heterogeneity; India showed the fastest increase (EAPC 3.05; 95% CI, 2.91-3.19), followed by South Africa (2.82; 2.64-3.00), and Brazil (2.36; 2.31-2.42), while China showed the smallest increase (0.87; 0.70-1.03).</p><p><strong>Conclusion: </strong>HFPG-attributable lung cancer burden in women aged ≥50 years rose substantially from 1990 to 2021, with disproportionate growth in older ages and clear SDI/BRICS differences, supporting integrated metabolic prevention within cancer control and healthy aging strategies.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148144253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modified Albumin-Bilirubin Grade and Alpha-Fetoprotein Score for Predicting Prognosis of Hepatocellular Carcinoma Patients Undergoing Conventional Transarterial Chemoembolization.","authors":"Manabu Hayashi, Kazumichi Abe, Tatsuro Sugaya, Naoto Abe, Yosuke Takahata, Masashi Fujita, Hiromasa Ohira","doi":"10.1159/000546334","DOIUrl":"10.1159/000546334","url":null,"abstract":"<p><strong>Introduction: </strong>Predicting post-treatment prognosis in hepatocellular carcinoma (HCC) patients undergoing conventional transarterial chemoembolization (cTACE) is challenging due to tumor heterogeneity. We here assessed the utility of the modified albumin-bilirubin grade and α-fetoprotein (mALF) score for predicting the prognosis of cTACE-treated HCC patients.</p><p><strong>Methods: </strong>This retrospective observational study included 206 early- and intermediate-stage HCC patients who had undergone cTACE. We calculated baseline and post-treatment mALF scores by assigning one point for a modified albumin-bilirubin grade of 2b or 3 and one point for an alpha-fetoprotein level of ≥100 ng/mL.</p><p><strong>Results: </strong>The baseline mALF scores were 0, 1, and 2 points for 66 patients (32%), 95 patients (47%), and 45 patients (21%), respectively, and their median survival times were 42.3 months, 21.1 months, and 14.0 months, respectively. The baseline mALF score was also associated with overall survival, independent of the Barcelona Clinic Liver Cancer stage and the tumor burden score (hazard ratio, 1.97; 95% confidence interval, 1.56-2.49; p < 0.001). One month after cTACE, the mALF score had decreased in 26 patients and increased in 31 patients. In those with a baseline mALF score of 0 or 1, the increased mALF score was significantly associated with shorter survival periods after cTACE.</p><p><strong>Conclusion: </strong>The baseline mALF score was useful in stratifying HCC patients undergoing cTACE, according to post-treatment prognosis. Increased mALF scores after cTACE were associated with poor prognosis in patients with a baseline mALF score of 0 or 1. Assessment of baseline and post-treatment mALF scores may help in predicting prognosis in HCC patients following cTACE.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"240-249"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism and Application Prospect of Noncoding RNA Regulating Tumor Cell Pyroptosis.","authors":"Wang Wan, Qiyang Mao, Zhuohong Ye, Dan Huang, Rongjing Zhang, Kangxian Wang, XueFeng Wang, QiaYu Wu, Zhu Liang, Chunyuan Chen","doi":"10.1159/000543102","DOIUrl":"10.1159/000543102","url":null,"abstract":"<p><strong>Background: </strong>Noncoding RNAs (ncRNAs), including microRNAs, lncRNAs, and circRNAs, play essential roles in physiological and pathological processes, including cancer, where they act as drivers or suppressors. Aberrant ncRNA expression in tumors has been linked to tumor promotion or suppression, making them potential cancer biomarkers. Pyroptosis, a newly discovered form of programmed cell death, is characterized by cell swelling, membrane rupture, and inflammation, offering a novel strategy for tumor elimination.</p><p><strong>Summary: </strong>Pyroptosis can activate anti-tumor immunity, while ncRNAs regulate pyroptosis pathways, influencing tumorigenesis through diverse mechanisms. However, the role of ncRNAs in pyroptosis, including potential initiators and their impact on tumor resistance, immunity, and cancer progression, remains unclear. The specific role of circRNAs in pyroptosis also requires further exploration.</p><p><strong>Key messages: </strong>This article explores the role of ncRNAs in pyroptosis, with a particular focus on ncRNA-mediated mechanisms, and highlights their potential as diagnostic and prognostic markers in cancer.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"181-200"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-Stratified Risk of Carboplatin-Induced Nausea and Vomiting in Lung Cancer Patients.","authors":"Koki Hashimoto, Takashi Yokokawa, Yuma Nonomiya, Naoki Shibata, Azusa Soejima, Kazuo Kobayashi, Yutaro Mae, Akiko Hasegawa, Takeshi Aoyama, Yoshikazu Tateai, Shuhei Ban, Kotono Nigata, Ryusei Abe, Kazuyoshi Kawakami, Hisanori Shimizu, Ryo Ariyasu, Noriko Yanagitani, Kaname Hasegawa, Takashi Kawaguchi, Masakazu Yamaguchi, Kenichi Suzuki","doi":"10.1159/000544875","DOIUrl":"10.1159/000544875","url":null,"abstract":"<p><strong>Introduction: </strong>Age has been reported as a risk factor for chemotherapy-induced nausea and vomiting. However, few reports have described risk factors for nausea and vomiting with carboplatin (CBDCA). This study investigated whether the incidence of CBDCA-induced nausea and vomiting differs with age, using 70 years as the cutoff.</p><p><strong>Methods: </strong>Patients who underwent CBDCA for lung cancer at the Cancer Institute Hospital of Japanese Foundation for Cancer Research between November 2020 and October 2023 were included in this retrospective study. The age cutoff was set at 70 years, with the complete response (CR; no vomiting/retching and no rescue medication) rate during the observation period as the endpoint.</p><p><strong>Results: </strong>Of the 198 patients included in the analysis, 114 (57.6%) were ≥70 years old. The CR rate was 36.9% for patients <70 years old and 61.4% for patients ≥70 years old (p = 0.001). In univariate analyses, age <70 years, female sex, no drinking history, no smoking history, and higher CBDCA dose were associated with non-CR. In multivariate analysis, age <70 years, no drinking history, and higher CBDCA dose were associated with non-CR.</p><p><strong>Conclusion: </strong>Age <70 years, no drinking history, and higher CBDCA dose were identified as risk factors for CBDCA-induced nausea and vomiting.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"125-136"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atezolizumab plus Bevacizumab Is Associated with Favorable Overall Survival over Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.","authors":"Hyung-Don Kim, Young-Gyu Park, Hyeyeon Hong, Sung Won Chung, Sejin Kim, Min-Hee Ryu, Baek-Yeol Ryoo, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Won-Mook Choi, Changhoon Yoo","doi":"10.1159/000545351","DOIUrl":"10.1159/000545351","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to compare the effectiveness outcomes of Child-Pugh class A patients with unresectable hepatocellular carcinoma (HCC) treated with first-line atezolizumab-bevacizumab and lenvatinib.</p><p><strong>Methods: </strong>This retrospective study included patients with Child-Pugh A unresectable HCC who were administered first-line treatment with either atezolizumab-bevacizumab (n = 368) or lenvatinib (n = 229) at Asan Medical Center (Seoul, Korea). Effectiveness outcomes were analyzed along with the inverse probability treatment weighting (IPTW) analysis to adjust for potential confounders.</p><p><strong>Results: </strong>Hepatitis B virus infection was the most common cause of HCC. With median follow-up duration of 11.9 for atezolizumab-bevacizumab and 20.9 months for the lenvatinib groups, patients treated with atezolizumab-bevacizumab exhibited superior progression-free survival (PFS) and overall survival (OS) than those treated with lenvatinib (median PFS 6.3 vs. 4.9 months, p = 0.031; and median OS 18.5 vs. 11.3 months, p < 0.001). After IPTW adjustment, atezolizumab-bevacizumab remained associated with favorable OS (median OS of 17.9 vs. 12.3 months, p = 0.010). Treatment with atezolizumab-bevacizumab was an independent factor of OS in both the entire and IPTW-adjusted cohorts. For patients with a viral etiology, the atezolizumab-bevacizumab group exhibited significantly longer OS than the lenvatinib group in both entire and IPTW-adjusted cohorts (p < 0.001 and p = 0.006, respectively). Conversely, both groups showed comparable OS among those with a nonviral etiology (p = 0.656 and p = 0.616, respectively).</p><p><strong>Conclusions: </strong>Atezolizumab-bevacizumab showed superior OS compared to lenvatinib in Asian patients with unresectable HCC.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"40-50"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Utility of the New Category by Number of Stations for Lymph Nodal Involvement in Non-Small Cell Lung Cancer.","authors":"Nozomu Motono, Takaki Mizoguchi, Masahito Ishikawa, Shun Iwai, Yoshihito Iijima, Hidetaka Uramoto","doi":"10.1159/000545002","DOIUrl":"10.1159/000545002","url":null,"abstract":"<p><strong>Introduction: </strong>In the ninth edition of the TNM staging system, the new nodal involvement (N) subcategories to N2 for single-station involvement (N2a) and multiple-station involvement (N2b) have been adopted. Although there are significant differences in survival rates for each group of pN categories in the ninth edition, it can be assumed that survival rates in pN1 and pN2a are relatively similar.</p><p><strong>Methods: </strong>We retrospectively evaluated the utility of the new category by number of stations such as none, single station, and multiple station for pN in 1,000 NSCLC patients treated by pulmonary resection.</p><p><strong>Result: </strong>Survival rates were significantly different among none, single station, and multiple station (5-year RFS: none: 79.6%, single station: 47.3%, multiple station: 24.2%, all groups, p < 0.01; 8-year OS: none: 78.7%, single station: 65.2%, multiple station: 33.6%, all groups, p < 0.01). There were significant differences among each group categorized by number of pN station in multivariate analysis for RFS (none vs. single station: p < 0.01, none vs. multiple station: p < 0.01, single station vs. multiple station: p < 0.01). There were significant differences among each group categorized by number of pN station in multivariate analysis for OS (none vs. single station: p = 0.04, none vs. multiple station: p < 0.01, single station vs. multiple station: p < 0.01).</p><p><strong>Conclusion: </strong>There were significant differences among none, single station, and multiple station in each survival curve and in multivariate analysis for both RFS and OS. This category by number of pN station without dependence of location for lymph nodal involvement might be the new classification of lymph node involvement.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"29-39"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of a General Large Language Model-Based Classification System to Retrieve Information about Oncological Trials.","authors":"Fabio Dennstädt, Paul Windisch, Irina Filchenko, Johannes Zink, Paul Martin Putora, Ahmed Shaheen, Roberto Gaio, Nikola Cihoric, Marie Wosny, Stefanie Aeppli, Max Schmerder, Mohamed Shelan, Janna Hastings","doi":"10.1159/000546946","DOIUrl":"10.1159/000546946","url":null,"abstract":"<p><strong>Introduction: </strong>The automated classification of clinical trials and key categories within the medical literature is increasingly relevant, particularly in oncology, as the volume of publications and trial reports continues to expand. Large language models (LLMs) may provide new opportunities for automating diverse classification tasks. They could be used for general-purpose text classification, retrieving information about oncological trials.</p><p><strong>Methods: </strong>A general text classification framework with adaptable prompt, model and categories for the classification was developed. The framework was tested with four datasets comprising nine binary classification questions related to oncological trials. Evaluation was conducted using a locally hosted Mixtral-8x7B-Instruct v0.1-GPTQ model and three cloud-based LLMs: Mixtral-8x7B-Instruct v0.1, Llama3.1-70B-Instruct, and Qwen-2.5-72B.</p><p><strong>Results: </strong>The system consistently produced valid responses with the local Mixtral-8x7B-Instruct model and the Llama3.1-70B-Instruct model. It achieved a response validity rate of 99.70% and 99.88% for the cloud-based Mixtral and Qwen models, respectively. Across all models, the framework achieved an overall accuracy of >94%, precision of >92%, recall of >90%, and an F1-score of >92%. Question-specific accuracy ranged from 86.33% to 99.83% for the local Mixtral model, 85.49%-99.83% for the cloud-based Mixtral model, 90.50%-99.83% for the Llama3.1 model, and 77.13%-99.83% for the Qwen model.</p><p><strong>Conclusion: </strong>The LLM-based classification framework exhibits robust accuracy and adaptability across various oncological trial classification tasks. While there remain some challenges such as strong prompt dependence and high computational and hardware demands, LLMs will play a crucial role in automating the classification of oncological trials and literature as the technology continues to advance.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"410-420"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Abemaciclib-Induced Serum Creatinine Elevation on Dose Adjustment of Concomitant Medications.","authors":"Kengo Umehara, Yoshitaka Saito, Shinya Takada, Mitsugu Yamamoto, Nobumoto Tomioka, Kenichi Watanabe, Hiroyuki Kawaguchi","doi":"10.1159/000548669","DOIUrl":"10.1159/000548669","url":null,"abstract":"<p><strong>Introduction: </strong>Abemaciclib (ABE) is a selective cyclin-dependent kinase 4/6 inhibitor widely used in breast cancer treatment. ABE inhibits renal tubular transporters, such as organic cation transporter 2, multidrug and toxin extrusion protein (MATE) 1, and MATE2-K, thereby suppressing creatinine excretion. This leads to a reversible increase in serum creatinine (Scr) without causing true renal injury. Since Scr is commonly used to assess renal function and guide medication dose adjustments, this effect may influence the management of concomitant renally excreted drugs. We aimed to evaluate the impact of ABE-induced Scr changes on the dosing of concomitant renally excreted medications in real-world clinical practice.</p><p><strong>Methods: </strong>In this retrospective observational study, we included female patients who initiated ABE at Hokkaido Cancer Center between March 1, 2018, and March 31, 2023. Renal function was classified based on the Kidney Disease: Improving Global Outcomes guidelines, using creatinine clearance (CCr) cutoff values of 60 mL/min and 30 mL/min. The primary endpoint was the proportion of patients whose renal function classification changed post-ABE initiation, based on the lowest CCr value recorded during treatment.</p><p><strong>Results: </strong>Of 221 patients included in this study, 30.8% had grade ≥2 Scr elevation at 1 month post-ABE initiation, increasing to 56.6% after 2 years. CCr significantly decreased after ABE initiation compared with that at baseline (median [interquartile range]: 44.5 [34.7-55.7] mL/min vs. 61.6 [49.3-81.1] mL/min, p < 0.01). After ABE discontinuation, CCr values returned to baseline levels. Overall, 50.2% of patients experienced a change in renal function classification after ABE initiation (p < 0.01), and 22.6% required dose adjustment owing to these changes.</p><p><strong>Conclusion: </strong>ABE administration led to Scr elevation and changes in renal function classification in approximately half of patients, impacting dose adjustment of concomitant renally excreted medications. Therefore, appropriate management methods, including cystatin C-based renal evaluation, are necessary.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"655-662"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145355568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updates and Review of Neoadjuvant Therapy for Resectable Pancreatic Cancer.","authors":"William Cobb, Daniel Rozefort, Chunghun Ji, Suhani Sehgal, Armando Rosales, Rajesh Sehgal","doi":"10.1159/000548583","DOIUrl":"10.1159/000548583","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic adenocarcinoma (PDAC) is a disease process that carries high morbidity and mortality and is suspected to supplant colorectal cancer as the second leading cause of cancer-related death in the USA. Resectable disease is considered no tumor contact with the celiac axis, common hepatic artery, or superior mesenteric artery and less than 180-degrees contact with portal vein or superior mesenteric vein. The current standard of care for resectable disease is surgery.</p><p><strong>Summary: </strong>There is an ongoing paradigm shift to consider neoadjuvant therapy (NAT) for initially resectable disease and this review aims to summarize the updates in NAT for resectable pancreatic cancer. We performed a literature search of NAT for resectable PDAC and reviewed pertinent literature for current treatment regimens, clinical trials comparing NAT to up-front resection, and other modalities in the treatment of PDAC.</p><p><strong>Key messages: </strong>Retrospective studies, recent completed prospective studies, and ongoing trials are showing an increased consideration for NAT for resectable PDAC compared with up-front surgery. Additionally, immunotherapy, cell therapy, and matrix-depleting therapy are promising new avenues in the treatment of pancreatic cancers.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"663-671"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145422323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}